Apremilast in comorbidities associated with psoriasis
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20260383Keywords:
Apremilast, Psoriasis, Cardiovascular diseaseAbstract
Psoriasis (PsO) is a multifactorial inflammatory disorder frequently associated with comorbidities such as cardiovascular disease (CVD), metabolic syndrome (MetS), and type 2 diabetes mellitus (DMII). Several studies have demonstrated a strong correlation between PsO and MetS, suggesting shared inflammatory mechanisms. Chronic inflammation contributes to both conditions, with cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-17, and IL-10 playing central roles. IL-17, in particular, modulates the interface between inflammation and metabolism by influencing glucose homeostasis and adipocyte function. Elevated TNF-α and IL-6 levels, characteristic of PsO, are implicated in insulin resistance, while IL-6 additionally promotes adipose lipolysis and hepatic gluconeogenesis, exacerbating metabolic dysfunction.
Metrics
References
Agarwal K, Das S, Kumar R, De A. Psoriasis and its Association with Metabolic Syndrome. Indian J Dermatol. 2023;68(3):274-7. DOI: https://doi.org/10.4103/ijd.ijd_418_23
Campione E, Zarabian N, Cosio T. Apremilast as a Potential Targeted Therapy for Metabolic Syndrome in Patients with Psoriasis: An Observational Analysis. Pharmaceuticals (Basel). 2024;17(8):989. DOI: https://doi.org/10.3390/ph17080989
Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem. Pharmacol. 2012;83(12):1583-90. DOI: https://doi.org/10.1016/j.bcp.2012.01.001
Ferguson LD, Cathcart S, Rimmer D, Semple G, Brooksbank K, Paterson C, et al. Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-Results of the immune metabolic associations in psoriatic arthritis study. Rheumatology. 2021;61(3):1026-34. DOI: https://doi.org/10.1093/rheumatology/keab474
Ong W, Gribble F, Reimann F, Lynch M, Houslay M, Baillie G, et al. The role of the PDE4D camp phosphodiesterase in the regulation of glucagon-like peptide-1 release. Br J Pharmacol. 2009;157(4):633-44. DOI: https://doi.org/10.1111/j.1476-5381.2009.00194.x
Filippi F, Patrizi A, Iezzi L, Carpanese MA, Conti A, Lasagni C, et al. Use of apremilast® in the psoriasis treatment: A real-life multicenter Italian experience. Ital J Dermatol Venereol. 2022;157(4):313-7. DOI: https://doi.org/10.23736/S2784-8671.21.07125-5
Guerra P, Di Cesare A, Rosi E, Scandagli I, Silvi G, Nunziati G, Prignano F. Effects on Lipid Profile after One Year of Apremilast Therapy in Patients with Psoriasis: A Monocentric Experience. Life. 2024;14:395. DOI: https://doi.org/10.3390/life14030395
Gelfand JM, Shin DB, Armstrong AW, Tyring SK, Blauvelt A, Gottlieb S, et al. Association of Apremilast with Vascular Inflammation and Cardiometabolic Function in Patients with Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial. JAMA Dermatol. 2022;158(12):1394-403. DOI: https://doi.org/10.1001/jamadermatol.2022.3862
Sui D, Yu H. Protective roles of apremilast via Sirtuin 1 in atherosclerosis. Bioengineered. 2022;13(5):13872-81. DOI: https://doi.org/10.1080/21655979.2022.2085390
Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: A phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75(6):1065-73. DOI: https://doi.org/10.1136/annrheumdis-2015-207963
Downloads
Published
How to Cite
Issue
Section
